Table 1. Baseline Characteristics Among the 3 Treatment Groups
VariableTocilizumabAnti–TNF‐αsDMARD
Patients, No.17914
Drug, No. (%)Tocilizumab=17 (100) Etanercept=7 (77.78)
Adalimumab=2 (32.32)
Methotrexate=6 (42.85)
Leflunomide=8 (63.15)
Age, y51.7 [44.52–58.90]47.0 [40.02–53.98]55.1 [48.60–61.55]
Female sex, No. (%)15 (88.2)7 (77.8)11 (78.6)
Erosive disease, No. (%)17 (100)8 (88.89)12 (85.71)
Rheumatoid factor, No. (%)16 (94.12)7 (77.78)12 (85.71)
Disease duration, y12.1 [8.39–15.84]10.7 [2.89–18.54]9.2 [4.63–13.80]
Statin users, No. (%)1 (5.88)4 (44.44)1 (7.14)
Diabetes mellitus, No. (%)1 (5.88)1 (11.11)0
Family history of CAD, No. (%)1 (5.88)2 (22.22)1 (7.14)
Active smokers, No. (%)1 (5.88)1 (11.11)1 (7.14)
Ex‐smokers, No. (%)7 (41.18)3 (33.33)3 (21.43)
Weight, kg69.5 [61.85–77.17]64.6 [55.11–74.09]72.6 [66.04–79.18]
Height, m1.61 [1.57–1.65]1.60 [1.56–1.64]1.62 [1.58–1.66]
BMI, kg/m226.7 [24.00–29.46]25.3 [21.09–29.48]27.8 [25.15–30.51]
Abdominal circumference, cm92.4 [85.49–99.22]90.1 [81.25–98.97]94.4 [88.80–100.06]
TC, mg/dL197.5 [177.59–217.36]185.1 [158.16–212.06]185.8 [169.76–201.81]
HDL‐C, mg/dL62.3 [52.47–72.12]58.8 [45.26–72.29]52.1 [45.33–58.96]
LDL‐C, mg/dL116.6 [101.03–132.19]108.6 [88.67–128.44]111.5 [99.04–123.94]
Triglycerides, mg/dL92.6 [77.33–107.96]88.9 [67.88–109.90]110.8 [83.41–138.16]
TC/HDL‐C3.36 [2.91–3.80]3.35 [2.64–4.06]3.75 [3.05–4.45]
CRP, mg/dL3.59 [1.84–5.35]1.62 [0.92–2.32]2.31 [1.00–3.61]
ESR, mm/h56.3 [37.33–75.30]37.7 [18.64–56.70]31.8 [17.78–45.92]
DAS28‐CRP5.87 [5.29–6.44]5.34 [4.22–6.47]5.15 [4.43–5.88]
HAQ‐DI1.88 [1.60–2.15]1.69 [1.07–2.32]1.23 [0.89–1.56]
FMD%3.43 [1.28–5.58]4.78 [2.13–7.42]2.87 [−2.17 to 7.91]
  • Values are expressed as mean [95% CI] or percentage as appropriate. Anti–TNF‐α indicates anti–tumor necrosis factor α; BMI, body mass index; CAD, coronary artery disease; DAS28‐CRP, Disease Activity Score of 28 joints, using C‐reactive protein (CRP); ESR, erythrocyte sedimentation rate; FMD%, flow‐mediated dilation percentage variation; HAQ‐DI, Health Assessment Questionnaire—Disability Index; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; sDMARD, synthetic disease‐modifying antirheumatic drug; TC, total cholesterol.